|
Originally published In Press as doi:10.1074/jbc.M204159200 on October 24, 2002
J. Biol. Chem., Vol. 277, Issue 52, 50725-50733, December 27, 2002
Protection from Pancreatitis by the Zymogen Granule
Membrane Protein Integral Membrane-associated Protein-1*
Takuji
Imamura ,
Minoru
Asada ,
Sherri K.
Vogt,
David
A.
Rudnick,
Mark E.
Lowe, and
Louis J.
Muglia§
From the Departments of Pediatrics, Molecular Biology and
Pharmacology, and Obstetrics and Gynecology, Washington University
School of Medicine and St. Louis Children's Hospital, St. Louis,
Missouri 63110
Received for publication, April 29, 2002, and in revised form, October 10, 2002
 |
ABSTRACT |
Pancreatitis is a common disease with substantial
morbidity and mortality. To better understand the mechanisms conferring sensitivity or resistance to pancreatitis, we have initiated the analysis of novel acinar cell proteins. Integral membrane-associated protein-1 (Itmap1) is a CUB (complement subcomponents C1r/C1s, sea
urchin Uegf protein, bone morphogenetic protein-1) and zona pellucida
(ZP) domain-containing protein we find prominently expressed in
pancreatic acinar cells. Within the acinar cell, Itmap1 localizes to
zymogen granule membranes. Although roles in epithelial
polarity, granule assembly, and mucosal protection have been postulated for CUB/ZP proteins, in vivo functions for these molecules
have not been proven. To determine the function of Itmap1, we generated Itmap1-deficient mice. Itmap1 / mice
demonstrate increased severity of secretagogue- and diet-induced pancreatitis in comparison to Itmap1+/+ mice.
In contrast to previous animal models exhibiting altered severity of
pancreatitis, Itmap1 deficiency results in impaired activation of
trypsin, an enzyme believed critical for initiating a cascade of
digestive zymogen activation during pancreatitis. Itmap1 deficiency
does not alter zymogen granule size, appearance, or the composition of
zymogen granule contents. Our results demonstrate that Itmap1 plays an
essential role in trypsinogen activation and that both impaired and
augmented trypsinogen activation can be associated with increased
severity of pancreatitis.
 |
INTRODUCTION |
Acute pancreatitis remains a significant cause of morbidity and
mortality in the United States (1, 2). These attacks often require
hospitalization, and ~10% of patients die. The treatment of
pancreatitis centers on supportive care coupled with close observation
for complications. No therapy alters the course of acute pancreatitis.
The lack of therapy stems, at least in part, from a paucity of
information about the events that led to pancreatic inflammation.
Virtually all theories about the pathogenesis of acute
pancreatitis have included autodigestion of the pancreas by the
digestive enzymes normally synthesized in the pancreatic acinar cells
(1, 2). In these models, some event triggers the inappropriate release
of digestive enzymes into the parenchyma of the pancreas. Whatever the
trigger, most authors believe that the insult causes the premature
activation of trypsinogen to trypsin within the acinar cell. As trypsin
accumulates, it activates other proenzymes (zymogens), and the combined
action of these proteases and lipases further damages the pancreas.
Several recent studies support the central role of
trypsinogen activation in the pathophysiology of pancreatitis. Most
patients with hereditary pancreatitis have a mutation in the gene
encoding cationic trypsinogen (3). The mutation may allow trypsin to accumulate in the acinar cell and activate other digestive enzymes. Studies with mice deficient in cathepsin B, a lysosomal hydrolase that
can convert trypsinogen to trypsin, support the importance of
trypsinogen activation and the fusion of lysosomes and zymogen granules
in the pathophysiology of pancreatitis (4). The cathepsin B-deficient
mice have decreased edema and cellular necrosis associated with
decreased trypsinogen activation in an experimental model of
pancreatitis induced by hyperstimulation with cerulein.
To protect the pancreas from the inappropriate activation
of trypsinogen and other zymogens, mechanisms have evolved that maintain the integrity of the pancreas (5). These mechanisms include
the synthesis and secretion of digestive enzymes as inactive zymogens,
the synthesis of protease inhibitors, the compartmentalization of
proenzymes in specialized zymogen granules destined for trafficking to
the apical plasma membrane, and the activation of proenzymes in the
duodenum. Together, these protective mechanisms prevent or limit the
cascade of proenzyme activation that results in tissue damage. For
acute pancreatitis to develop, these protective mechanisms must fail
and permit the untimely activation of digestive enzymes by trypsin.
Only in the rare patient with hereditary pancreatitis is there a clue
as to how the protective mechanisms might fail in acute pancreatitis
(3). For the majority of patients with acute pancreatitis no mechanism
is known. Other factors must predispose to premature trypsinogen
activation or, alternatively, entirely distinct mechanisms may lead to
pancreatitis in these patients. Further insight into these mechanisms
may lead to novel strategies for identifying individuals at risk for
pancreatitis and to more effective therapies for this potentially
life-threatening disorder.
To further understand the mechanisms involved in protecting the acinar
cell from digestive damage, we have evaluated the function of a novel
acinar cell zona pellucida
(ZP)1 domain-containing
protein Itmap1 (6). ZP domain proteins such as uromodullin, the
pancreatic ductal protein muclin, the zymogen granule protein GP2, and
the inner ear protein -tectorin are often found in fibrillar or
gelatinous compartments of the extracellular matrix, with the ZP domain
serving as a filament-organizing motif (7). This filamentous structure
may contribute to mucosal protection by providing barrier function.
Alternatively, ZP domain proteins have also been implicated in
trafficking of secretory granules in the pancreas (8). In this study,
we demonstrate that Itmap1 is a protein tightly associated with zymogen
granule membranes and that Itmap1 attenuates the severity of pancreatitis.
 |
EXPERIMENTAL PROCEDURES |
Generation of Itmap1 / Mice--
We isolated an
861-bp cDNA encoding Itmap1 using gestation day 16 uterus
poly(A)+ RNA as "tester" and gestation day 19 poly(A)+ RNA as "driver" in a PCR-Select cDNA
subtraction kit (Clontech, Palo Alto, CA).
Random-primer-labeled fragments of the Itmap1 cDNA were used to
screen a murine 129Sv genomic DNA library (Stratagene, La Jolla, CA).
Two genomic clones were isolated and used for sequence analysis and
identification of intron-exon boundaries.
To generate the vector for homologous recombination, a 3.3-kb
XbaI-EcoRI fragment beginning in intron 1 was
first cloned into XbaI- and EcoRI-digested pPNT
(9) to generate pPNT.Itmap1-3'. Next, the 3.8-kb
NotI-BamHI fragment ending 1.6-kb 5' to the
transcription initiation site was excised from pBluescript SK II+ as a
NotI-XhoI fragment and cloned into pPNT.Itmap1-3'
to generate the final targeting vector pPNT Itmap1. The TC1 line of
embryonic stem (ES) cells (10) underwent electroporation with
linearized pPNT Itmap1 and selection as previously described (11). ES
clones having undergone appropriate homologous recombination were
identified by Southern blot analysis employing a 240-bp
EcoRI-BamHI probe external to the
Itmap1 genomic sequences in the targeting vector. Two
independent clones were selected for blastocyst injection, each of
which proved capable of germ line transmission. Mice used for these
experiments were of a mixed 129 × Black Swiss background; similar
results have been obtained on mice of mixed 129 × C57BL/6 or
inbred 129SvJ backgrounds.
Immunohistochemistry--
A 488-bp cDNA fragment extending
from nucleotide 1048 to 1535 of the Itmap1 cDNA
(GenBankTM accession number U69699) was cloned into the
XhoI and KpnI sites of the bacterial expression
vector pBAD/HisC (Invitrogen, Carlsbad, CA) for generation of a
recombinant protein fragment. After purification from arabinose-induced
bacteria, the protein fragment was injected into two rabbits for
generation of anti-Itmap1 polyclonal antisera. Serum from rabbit 67418 was utilized for the current studies at a dilution of 1:5000 on
paraformaldehyde-fixed, paraffin-embedded tissues cut at 5 µm.
Antibody binding was visualized with a goat anti-rabbit Cy3 secondary
antibody. Sections were counterstained with
4',6-diamidino-2-phenylindole for localization of cell nuclei.
In Situ Hybridization--
Tissues were fixed by immersion in
diethylpyrocarbonate-treated 4% paraformaldehyde in PBS for 24 h
at 4 °C. Samples were then cryopreserved in 10% sucrose in PBS, and
embedded in OCT compound (Miles, Elkhart, IN) for sectioning on a
cryostat. 14-µm sections were thaw-mounted onto Superfrost Plus
slides (Fisher Scientific, Pittsburgh, PA) and hybridized to an
[ -33P]UTP-labeled 861-base Itmap1 riboprobe as
previously described (12). After washing, slides were exposed to Kodak
NTB-2 emulsion (Eastman Kodak Co., Rochester, NY) for 3-10 days and
developed. Immediately adjacent slides were counterstained with
hematoxylin and eosin.
Electron Microscopy--
For ultrastructural analysis, pancreata
were minced into 1-mm3 pieces, immersion-fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer at 4 °C
overnight, and postfixed in 1.25% osmium tetroxide. Samples were
thin-sectioned in Polybed 812 (Polysciences, Warrington, PA),
poststained with uranyl acetate and lead citrate, and visualized on a
Zeiss 902 microscope (Zeiss, Thornwood, NY). For immunoelectron
microscopy, pancreata were fixed in 8% paraformaldehyde-PBS overnight
at 4 °C, rinsed three times in PBS, infused in 2 M
sucrose-polyvinylpyrrolidone, and processed for ultracryotomy.
Ultrathin sections were prepared and incubated with blocking buffer
containing 10% goat serum. Immunolabeling was done by incubating with
the anti-Itmap1 antibody for 2 h, followed by secondary antibody
(12-nm-gold-labeled goat anti-rabbit) for 1 h. After washing,
sections were stained with uranyl acetate and embedded in methyl
cellulose. Specimens were visualized with a Zeiss 902 microscope, and
photographs were recorded with Kodak EM film.
Zymogen Granule Enrichment--
Pancreatic acinar cell zymogen
granules were prepared from adult mice as previously described (13,
14). Two to three pancreata were placed in ice-cold 250 mM
sucrose, 5 mM MOPS (pH 7.0), 0.1 mM
MgSO4 containing one MiniComplete tablet (Roche Molecular
Biochemicals, Indianapolis, IN) per 10 ml of buffer. The pancreata were
homogenized for 30 s with a Polytron on setting 8000 followed by
four strokes with a loose-fitting glass Dounce homogenizer. The mixture
was centrifuged at 150 × g for 15 min, and the
supernatant was re-centrifuged at 1300 × g for 15 min.
The pellet was mixed with 40% Percoll, 250 mM sucrose, 50 mM MES (pH 5.5), 0.1 mM MgSO4, 2 mM EGTA, and one MiniComplete tablet per 10 ml. The zymogen
granules were banded by centrifugation at 100,000 × g
for 20 min. The zymogen granules were washed by dilution with
homogenization buffer and centrifugation at 1300 × g
for 10 min. The granules were osmotically lysed and the membranes
isolated and washed as described (14). The first post-lysis supernatant
containing the granule contents was also saved for analysis. Enrichment
of zymogen granule contents and membranes was confirmed determining the
relative abundance of amylase in each preparation by Western blot
analysis with an anti-amylase primary antibody (data not shown).
RNA and Protein Analyses--
Ten micrograms of total RNA was
subjected to electrophoresis through 1.2% agarose-formaldehyde gels
and transferred to nitrocellulose membranes.
[ -32P]UTP-labeled RNA probes specific for mouse Itmap1
mRNA, cyclophilin mRNA, or 18 S ribosomal RNA were hybridized
at 60 °C in 50% formamide-containing buffer as previously described
(15).
Total cellular membrane proteins and zymogen granule membrane proteins
and contents were subjected to 8% SDS-PAGE electrophoresis and then
transferred to nitrocellulose membranes. Itmap1 was detected with our
rabbit anti-Itmap1 primary antibody used at a 1:2000 dilution (total
membrane proteins) or 1:5000 dilution (zymogen granule-enriched
membranes and contents) and visualized using an enhanced
chemiluminescent detection kit (Amersham Biosciences, Arlington
Heights, IL). Zymogen granule glycoproteins were detected with
peroxidase-conjugated concanavalin A and wheat-germ agglutinin after
electrophoretic separation and transfer to nitrocellulose membranes
(16). Ponceau S staining of membranes confirmed equivalent protein
loading and transfer. Carbohydrate residues were removed from zymogen
granule membrane glycoproteins by digestion with peptide:
N-glycosidase F according to the manufacturer's recommended protocol (New England BioLabs, Inc., Beverly, MA). For Pronase digestion the zymogen granules were isolated and washed as above except
that the last wash did not contain protease inhibitors. The granules
were suspended in 1.0 ml of wash buffer divided into four 300-µl
aliquots. The granules were incubated on ice for 10 min in buffer
alone, buffer with 7% Nonidet P (NP)-40, buffer with 0.33 unit of
Pronase, and buffer with 7% Nonidet P-40 and 0.33 unit of Pronase. The
reaction was stopped by adding 700 µl of SDS-sample buffer containing
one MiniComplete tablet (Roche Molecular Biochemicals, Indianapolis,
IN) per 10 ml of buffer followed by boiling for 5 min.
Two-dimensional Gel Electrophoresis--
Forty micrograms of
protein from zymogen granule contents were diluted in rehydration
solution (Amersham Biosciences, Piscataway, NJ) containing 8 M urea and 2% CHAPS and loaded onto pH 3-10 gradient isoelectric focusing (IEF) strips for first-dimension separation on the
basis of IEF point. Samples were focused for ~12,000 V-h to
equilibrium. The focused samples were then loaded onto 4-12% gradient
acrylamide gels for second dimension separation by SDS-PAGE on the
basis of size. Gels were stained with Coomassie Brilliant Blue
G-Colloidal (Sigma, St. Louis, MO). Individual protein spots on scanned
images were quantitated densitometrically using Scion Image (Scion
Corp., Frederick, MD) software from replicate gels.
Pancreatitis Induction--
For cerulein-induced pancreatitis
(17-19), 2- to 3-month-old male Itmap1+/+ and
Itmap1 / mice were injected with seven doses
of either 50 µg/kg cerulein in normal saline or normal saline at
hourly intervals following an overnight fast and ad libitum
access to water. 8 h (vehicle and cerulein-injected mice) and
24 h (cerulein-injected mice) after the initial injection, blood
was obtained by retro-orbital phlebotomy for measurement of amylase and
lipase activity on a Vitros 250 analyzer (Ortho Clinical Diagnostics,
Rochester, NY) using reagents supplied by the instrument manufacturer
(n = 6-9 per group). 8 h after the initial
injections, an additional n = 4-6 mice were
euthanized, and their pancreata were isolated and weighed. Pancreata
were then immersion-fixed in 4% paraformaldehyde, embedded in
paraffin, cut into 5-µm sections, and stained with hematoxylin and
eosin. Photographs of coded sections (4-6 fields per mouse) were
examined by two independent observers and scored for necrosis using the
following semi-quantitative scale: 0, no necrosis; 1, periductal
necrosis (<5%); 2, focal necrosis (5-20%); 3, diffuse parenchymal
necrosis (>20%). Additional sections were evaluated for acinar cell
apoptosis by TUNEL-staining employing an Apoptag peroxidase kit
(Intergen Co., Purchase, NY). Sections were counterstained with methyl
green after the peroxidase reaction. Quantitation of apoptotic cells
was performed on n = 4 saline-treated mice and
n = 4-5 cerulein-treated mice. The average number of apoptotic nuclei per ×400 field was calculated from three
(saline) or eight (cerulein) random, independent fields per mouse.
For the measurement of intra-pancreatic enzyme activities, the pancreas
was removed at the indicated times after initiation of cerulein
injections and immediately frozen in liquid nitrogen and stored at
80 °C. For the measurement of trypsin activity, the tissue was
thawed and homogenized in ice-cold 5 mM MOPS (pH 6.5), 1 mM MgSO4, and 250 mM sucrose (4).
The sample was sonicated for 30 s and centrifuged for 5 min at
16,000 × g. The same buffer supplemented with 1 mM EDTA and 0.1% Triton X-100 was used to prepare the
sample for assay of the trypsinogen activation peptide (TAP). After
homogenization, the sample was boiled for 10 min, and a supernatant was
prepared by centrifugation at 16,000 × g for 5 min.
For myeloperoxidase (MPO) assays, pancreatic tissue was homogenized
in 20 mM potassium phosphate (pH 7.0) and centrifuged for
10 min at 10,000 × g (4). The pellet was resuspended
in 50 mM potassium phosphate buffer (pH 6.0) containing
0.5% cetyltrimethylammonium bromide. Afterward the sample was
frozen and thawed four times and sonicated for 10 s, and the
supernatant was prepared by centrifugation at 10,000 × g for 5 min. Protein concentrations in the samples were
determined by the BCA method (Pierce, Rockford, IL). Trypsin, TAP, and
MPO were measured by published methods (4). Relative amounts of
trypsinogen were determined by protein immunoblot of pancreatic
extracts with a rabbit polyclonal antibody against trypsinogen (Abcam
Ltd., Cambridge, UK). Relative abundance of trypsinogen on scanned
immunoblots was determined by densitometric analysis with results
expressed as normalized absorbance/mg of total protein.
Cathepsin B activity was determined with
-N-benzyloxycarbonyl-Arg-Arg- -naphthylamide as
described previously (20). Cathepsin B activity is reported as relative
units (change in fluorescence/min)/mg of total protein. Each assay was
done in triplicate on samples isolated from three different mice of
each genotype at each time point. To evaluate cerulein-induced
signaling in pancreata from mice of each genotype, the cerulein
concentration dependence of amylase secretion from pancreatic snips
harvested 1-2 h prior to stimulation was measured in triplicate as
previously described (21).
Diet-induced pancreatitis was precipitated by placing 2- to 3-month-old
Itmap1+/+ (n = 17) and
Itmap1 / (n = 18) female mice
(body weight, 25 ± 0.5 g) on choline-deficient, 0.5%
ethionine-supplemented (CDE) chow (Dyets, Inc., Bethlehem, PA) as
previously described (22, 23). We chose to test this age range of mice,
because they are somewhat more resistant to morbidity in this model of
pancreatitis. After an overnight fast, mice received the CDE chow for
48 h and then were returned to normal rodent chow. Samples for
serum enzymes (n = 8 per genotype) and pancreatic
histology (n = 3 per genotype) were obtained 72 h
after the initiation of the CDE diet.
Statistical Methods--
All results are expressed as mean ± S.E. unless otherwise indicated. Statistical analysis was by
analysis of variance, with p 0.05 considered
significant. Differences in mortality were assessed for significance by
Chi-square analysis. Statistical analysis of the semi-quantitative
assessment of acinar cell necrosis was by Mann-Whitney rank sum.
 |
RESULTS |
In Vivo Expression of Itmap1--
Itmap1 was first identified as a
novel ZP protein induced specifically in late gestation mouse uterus
(6). In accord with this previous report, we found no expression of
Itmap1 in non-gravid mouse uterus and high level expression in
mid-to-late gestation uterus (Fig.
1a). Within the uterus, Itmap1
expression localized exclusively to the epithelium (Fig.
1b). A general tissue survey in non-gravid mice was notable
for high levels of Itmap1 expression in the pancreas, a site not
previously evaluated for Itmap1 expression. In situ
hybridization to histological sections of pancreas demonstrated Itmap1
mRNA expression in acinar cells but not ductal epithelium (Fig.
1c). Other tissues, including spleen, stomach, kidney,
thymus, ileum, and colon did not express Itmap1 mRNA (data not
shown).

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of Itmap1 in the pancreas and
uterus. a, Northern blot analysis. Total
cellular RNA from non-gravid (NG) and 18.5-day gestation
uterus and two adult pancreata was hybridized to either an Itmap1 probe
or an 18 S ribosomal RNA probe to control for sample loading and
recovery. b, in situ hybridization localization
of Itmap1 mRNA in day 16 gestation uterus. The upper
panel demonstrates the locations of the uterine endometrium
(E) and myometrium (M), and ovarian corpus luteum
(CL) on a hematoxylin and eosin-stained section. Silver
deposition viewed by dark field microscopy reveals restriction of
Itmap1 mRNA to the endometrium (lower panel).
c, in situ hybridization localization of Itmap1
mRNA in the pancreas (upper panel, hematoxylin and
eosin-stained frozen section; lower panel, dark field).
Itmap1 hybridization occurs throughout the acinar cell population but
not the ductal cells (indicated by the arrows).
|
|
Subcellular Localization of Itmap1--
To define the cellular
distribution of Itmap1, we generated a rabbit polyclonal anti-serum
against the junction of the CUB and ZP domains of Itmap1. By
immunofluorescence, this antiserum detected Itmap1 immunoreactivity
throughout the acinar cell population of the pancreas (Fig.
2a). The staining co-localized
with zymogen granules. We confirmed that Itmap1 resides in the zymogen
granules by immunoelectron microscopy (Fig. 2b). Grains were
only associated with zymogen granules. In the uterus, the anti-Itmap1
antibody also stained granular structures in the apical region of the
epithelium (data not shown). This pattern of expression was specific
for Itmap1 and not other ZP domain proteins, because
Itmap1 / mice (described below) failed to
demonstrate any immunoreactivity.

View larger version (70K):
[in this window]
[in a new window]
|
Fig. 2.
Immunohistochemical localization of
Itmap1. a, Itmap1 immunoreactivity (upper
panels, orange) was detected with a rabbit polyclonal
anti-Itmap1 anti-serum in Itmap1+/+, but not
Itmap1 / , zymogen granules within the
pancreas (lower panels, phase-contrast image).
Sections were counterstained with 4',6-diamidino-2-phenylindole for
localization of nuclei (blue). Magnification, ×100.
b, immunoelectron microscopic detection of Itmap1
immunoreactivity in zymogen granules of
Itmap1+/+ mice. Deposition of immunogold beads
is noted predominantly on the zymogen granule membrane
(arrows). Mitochondria (M) are unstained.
|
|
The amino acid sequence of Itmap1 contains a predicted signal peptide
and transmembrane domain indicating that Itmap1 should localize to a
cellular membrane. To determine if Itmap1 associates with membranes, we
performed Western blots on preparations of total membranes and of
zymogen granule-enriched membranes from both wild type and
Itmap1 / mice. Our antibody detected a
strongly positive 110-kDa protein in total cellular membrane
preparations from wild type pancreas and uterus (Fig.
3a). In contrast, only weak,
nonspecific bands were detected in membranes prepared from
Itmap1 / mice (Fig. 3a) and when
pre-immune serum was substituted for the anti-Itmap1 antibody (data not
shown). A protein of identical size was also present in
alkali-extracted zymogen granule-enriched membranes from wild type but
not Itmap1-deficient mice (Fig. 3b). Itmap1 reactivity was
not present in zymogen granule contents. Thus, Itmap1 is tightly
associated with zymogen granule membranes, and, by virtue of its
predicted transmembrane domain, likely to be an integral membrane
protein.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
Western blot analysis of Itmap1.
a, detection of Itmap1 in pancreatic or uterine total
membrane proteins. An immunoreactive protein of ~110 kDa
(arrow) is found in Itmap1+/+, but
not Itmap1 / , total membrane protein
extracts. b, detection of Itmap1 in zymogen granule
membranes, but not zymogen granule contents, of
Itmap1+/+ mice. Equivalent loading of zymogen
granule proteins was confirmed by Ponceau S membranes and lectin
binding (not shown). c, orientation of Itmap1 in the zymogen
granule. Western blot analysis of Itmap1 in isolated zymogen granules
with and without protease (Pronase) and detergent (Nonidet P-40)
treatment. Itmap1 immunoreactivity is abolished with protease treatment
only when zymogen granules are permeabilized with Nonidet P-40.
d, Western blot analysis of Itmap1 with and without
digestion of zymogen granule membrane glycoproteins with peptide:
N-glycosidase F (PNGase F). Reduction in size of
the Itmap1 immunoreactive band to a molecular weight consistent with
the translated cDNA is observed.
|
|
To determine whether the larger amino-terminal CUB/ZP portion of Itmap1
resides within or outside the zymogen granule, we subjected isolated
zymogen granules to protease digestion with or without permeabilization
with the detergent Nonidet P-40. Itmap1 immunoreactivity was abolished
with Pronase treatment only after permeabilization of the zymogen
granules with detergent, demonstrating that the CUB and ZP domains
reside within the zymogen granule (Fig. 3c).
Because the Itmap1 cDNA sequence predicts a product of 69 kDa and
our antiserum recognizes a product of ~110 kDa, we investigated the
possibility that post-translational glycosylation of Itmap1 explained
the size difference. Western blot analysis of zymogen granule membrane
proteins with the anti-Itmap1 antibody after digestion with peptide:
N-glycosidase F resulted in disappearance of the 110-kDa
protein band, and appearance of a new 69-kDa immunoreactive band,
confirming that the observed size of mature Itmap1 results from
glycosylation (Fig. 3d).
Generation and Characterization of Itmap1 /
Mice--
To determine the role of Itmap1 in zymogen granule function
in vivo, we generated Itmap1 /
mice by homologous recombination in embryonic stem cells. The Itmap1 gene consists of eight exons encompassing ~13 kb of
mouse genomic DNA (Fig. 4a).
In our targeting vector, we replaced exon 1, encoding the translation
start site and first 27 amino acids, and 1.6 kb 5' to the transcription
initiation region, with a phosphoglycerate kinase-neomycin resistance
cassette (Fig. 4b). Two independently targeted clones were
selected for microinjection, and both proved capable of germ line
transmission. Similar results were obtained with
Itmap1 / mice arising from each clone. To
ensure that deletion of the Itmap1 transcription promoter
region and exon 1 resulted in a null allele, we performed RNA blot
analysis of uterus RNA from gravid mice at 18.5 days of gestation
utilizing a hybridization probe detecting mRNA sequences 3' to the
deleted region. Robust Itmap1 mRNA expression was found in
Itmap1+/+ mice, and Itmap1 mRNA was absent
in Itmap1 / mice (Fig. 4c).
Itmap1 / mice exhibit normal growth,
longevity, and fertility when compared with
Itmap1+/+ littermates.
Itmap1 / females have normal timing for
parturition, reproducibly delivering viable litters at 19.5 days of
gestation. Zymogen granule size (Itmap1+/+
0.81 ± 0.02 µm versus
Itmap1 / 0.78 ± 0.2 µm;
n = 3 mice per group, 40 granules measured per animal)
and appearance by electron microscopy did not differ between Itmap1+/+ and Itmap1 /
mice (Fig. 4d).

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 4.
Targeted inactivation of
Itmap1. a, structure of the
Itmap1 gene. Exons are indicated by boxes, with
the untranslated regions stippled. Regions coding for the
CUB, zona pellucida (ZP), and putative transmembrane
(TM) domains are indicated. A subset of restriction sites is
shown for relative orientation. B, BamHI;
X, XbaI; E, EcoRI.
b, strategy for homologous recombination. Exon 1 and a
portion of the 5'-flanking region are replaced by a neomycin
(neo) selection cassette. A herpes simplex virus thymidine
kinase (TK) cassette was also included in the targeting
vector to provide negative selection. WT, wild type.
c, Northern blot analysis of total day-18.5 gestation
uterine RNA from Itmap1 / and
Itmap1+/+ mice hybridized to Itmap1 and
cyclophilin (cyc) antisense riboprobes. d,
electron microscopic analysis of zymogen granules. Magnification,
×7000.
|
|
Recent studies evaluating other pancreatic ZP proteins suggest that
they may be involved in the intracellular trafficking of secretory
granules and in the regulated exocrine transport of digestive enzymes
(8) or play other roles in maintenance of mucosal integrity (24, 25).
Based upon its structure and pattern of cellular distribution, we
hypothesized that Itmap1 could serve a role in maintaining pancreatic
integrity. We initiated our evaluation of possible differences in
responses to injury in the pancreas by measuring the severity of
cerulein-induced pancreatitis in Itmap1+/+ and
Itmap1 / mice. Repetitive administration of
cerulein, a cholecystokinin analogue, induces an acute hyperstimulation
pancreatitis associated with elevated serum amylase and lipase
concentrations, and interstitial pancreatic edema (17-19).
Cerulein-induced pancreatitis caused no mortality in either
Itmap1+/+ or Itmap1 /
mice. Itmap1 / mice, however, demonstrated
increased severity of pancreatitis histologically, with greater edema
causing wider separation between pancreatic lobules and disruption of
acini (Fig. 5). The histological appearance of greater edema in the Itmap1 /
mice was confirmed by greater pancreatic wet weight after cerulein hyperstimulation (Fig. 6a).
Semi-quantitative analyses of necrotic acinar cells indicated a mild
increase in necrosis in Itmap1 / compared
with Itmap1+/+ mice (p = 0.027;
data not shown). Additionally, Itmap1 / mice
had significantly increased numbers of apoptotic acinar cells after
cerulein treatment in comparison to Itmap1+/+
controls (Fig. 6b). Analysis of serum amylase and lipase
levels (Fig. 6c) revealed a statistically significant
elevation in basal lipase concentration in the
Itmap1 / mice
(Itmap1+/+ 786 ± 117 units/liter
versus Itmap1 / 1189 ± 112 units/liter; p < 0.05). At 8 and 24 h after
cerulein administration, lipase levels rose significantly in both
groups and were 38 and 56% higher in the
Itmap1 / mice when compared with
Itmap1+/+ mice (p < 0.05 and
p < 0.005, respectively), again in accord with greater
pancreatic damage. The greater severity of pancreatitis in
Itmap1 / mice is unlikely to arise from
altered intracellular cerulein-induced signaling because pancreatic
snips harvested from Itmap1 / and
Itmap1+/+ mice show very similar patterns of
amylase secretion as a function of cerulein concentration (Fig.
6d).

View larger version (110K):
[in this window]
[in a new window]
|
Fig. 5.
Pancreatic histology during pancreatitis in
Itmap1+/+ and
Itmap1 / mice. Representative
hematoxylin and eosin-stained paraffin sections of control
saline-injected, cerulein-injected, and choline-deficient,
ethionine-supplemented (CDE)-diet-treated mice. Edema is visualized as
increased intralobular separation in cerulein and CDE groups. Prominent
cellular necrosis is found in the Itmap1 /
CDE group.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Sequelae of pancreatitis in
Itmap1+/+ and
Itmap1 / mice. a,
pancreatic weight during cerulein-induced pancreatitis. *,
p < 0.05 versus cerulein-treated
Itmap1+/+ mice. b, induction acinar
cell apoptosis during cerulein-induced pancreatitis. Number of
TUNEL-positive acinar cells per ×400 magnification field is shown as a
function of treatment and genotype. *, p < 0.05 versus cerulein-treated Itmap1+/+
mice. c, serum amylase and lipase measurement during
cerulein and CDE-diet pancreatitis. *, p < 0.05; **,
p 0.01 versus
Itmap1+/+ enzyme group at same time point.
d, cerulein concentration dependence of amylase secretion
from pancreatic snips in Itmap1+/+ and
Itmap1 / mice. Amylase released into the
media after the addition of cerulein for 30 min is shown normalized to
the vehicle controls. Mean ± S.E. is displayed from triplicate
samples for each concentration and genotype. Differences between
genotypes were not statistically significant. e, survival
curve with CDE diet. Overall survival significantly differed between
Itmap1+/+ and Itmap1 /
mice (p < 0.05).
|
|
We next determined the response of Itmap1 /
mice to the more severe hemorrhagic pancreatitis induced by
administration of a choline-deficient, ethionine-containing (CDE) diet
(22, 23, 26). The Itmap1 / mice demonstrated
greater acinar cell necrosis and tissue edema after 2 days of the CDE
diet (Fig. 5). Consistent with the greater degree of histological
damage, Itmap1 / mice had markedly elevated
serum amylase and lipase levels at the same time (Fig. 6c).
Finally, the CDE diet was associated with only 53% survival in the
Itmap1 / mice, significantly reduced from the
93% survival rate in the Itmap1+/+ mice (Fig.
6e). Thus, with two different precipitants of pancreatitis, deficiency of Itmap1 results in greater disease severity.
To gain further insight into the mechanism by which Itmap1 limited the
severity of disease, we evaluated trypsin activation during the course
of cerulein-induced pancreatitis. Both trypsinogen-activation peptide
(TAP) concentration and trypsin activity were measured (Fig.
7, a and b). In the
pancreas from wild type mice, both TAP and trypsin increased above
background by 2 h after the initial cerulein injection. A smaller
rise in TAP and trypsin was seen in the pancreas from
Itmap1 / mice. The difference between the TAP
levels of the Itmap1+/+ and
Itmap1 / mice was statistically significant
at 8 h (p = 0.002). The differences between
trypsin levels were statistically significant at 2 h
(p = 0.002) and 8 h (p = 0.001).
The difference in activated trypsin was not due to lower amounts of
trypsinogen in the pancreas at baseline
(Itmap1+/+ 0.42 ± 0.08 and
Itmap1 / 0.47 ± 0.07 relative
absorbance/mg of protein) or 8 h after cerulein administration
(Itmap1+/+ 0.79 ± 0.11 and
Itmap1 / 0.84 ± 0.06 relative
absorbance/mg of protein). There was also no difference in pancreatic
cathepsin B content in the pancreas between genotypes at baseline
(Itmap1+/+ 0.94 ± 0.06 and
Itmap1 / 0.84 + 0.05 relative units/mg of
protein) or 8 h after cerulein administration
(Itmap1+/+ 0.80 ± 0.05 and
Itmap1 / 0.80 ± 0.07 relative units/mg
of protein).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 7.
Trypsin activation and inflammatory cell
infiltration in during cerulein-induced pancreatitis in
Itmap1+/+ and
Itmap1 / mice. Time course of TAP
production (a), trypsin activity (b), and
myeloperoxidase activity (c), in the pancreas after
initiation of cerulein injections at time zero. *, p < 0.005.
|
|
We next measured myeloperoxidase (MPO) activity to assess the effect of
Itmap1 deficiency on leukocyte infiltration during pancreatitis.
The induction of pancreatitis was associated with an increase in MPO
activity in the pancreas, but there was no difference in the MPO levels
observed in pancreas of the Itmap1+/+ and
Itmap1 / mice (Fig. 7c). This
finding suggests that Itmap1 does not dampen the inflammatory response
in acute pancreatitis.
Our above analyses of trypsin activity and TAP production suggest that
Itmap1 does not protect against pancreatitis by limiting the activation
of trypsin but, instead, is essential for normal trypsin activation.
One testable hypothesis for how Itmap1 regulates trypsin activation and
modifies the course of pancreatitis is that Itmap1 plays a role in
sorting proteins into the zymogen granule. Lectin staining of zymogen
granule membranes revealed no alteration in zymogen granule membrane
glycoproteins in Itmap1 / mice other than
Itmap1 itself (data not shown). To determine if Itmap1 deficiency
alters the composition of zymogen granule contents, we performed
proteomic analyses comparing contents of isolated
Itmap1+/+ and Itmap1 /
zymogen granules. Two-dimensional acrylamide gel electrophoresis (Fig.
8) followed by densitometric analysis
(data not shown) of replicate stained gels for each genotype revealed
an identical spectrum and relative abundance of detectable proteins
between genotypes.

View larger version (103K):
[in this window]
[in a new window]
|
Fig. 8.
Proteomic analysis of isolated zymogen
granule contents. First-dimension separation of granule contents
proteins was performed on isoelectric focusing strips. The focused
samples were then loaded onto 4-12% gradient acrylamide gels for
second-dimension separation by SDS-PAGE on the basis of size. Shown are
representative Coomassie Brilliant Blue G-colloidal-stained gels of
granule contents of each genotype. M, molecular weight
ladder.
|
|
 |
DISCUSSION |
Our findings identify several important biological properties of
Itmap1 and provide information about the in vivo function of
this novel ZP and CUB domain protein. To date, the pancreas and the
pregnant uterus are the only known sites of Itmap1 expression. In both
organs, immunohistochemistry with anti-Itmap1 antibodies localized
Itmap1 to cytoplasmic granules. Additional analysis of zymogen granule
membranes from pancreatic acinar cells confirmed the presence of Itmap1
on these membranes. The inability to remove Itmap1 from zymogen granule
membranes with high salt and alkali washes demonstrated tight
association of Itmap1 with these membranes. Itmap1 is likely to be an
integral membrane protein that is associated with the membrane through
a putative transmembrane domain near the carboxyl terminus of the
predicted protein sequence, although glycosylphosphatidylinositol
linkage has not been excluded. Furthermore, Itmap1 is oriented such
that the CUB and ZP domains are within the zymogen granule. Although
Itmap1 was initially identified as a protein induced in late gestation
mouse uterus (6), implicating it in the maintenance of pregnancy or
progression of labor, we find no overt consequence of Itmap1 loss
during pregnancy. In contrast, we showed that Itmap1 alters the course
of acute pancreatitis induced by cerulein hyperstimulation or by a CDE
diet. The largest effect was found in the CDE diet model of necrotizing
pancreatitis. In this model, the mortality of the Itmap1-deficient mice
increased almost 7-fold.
To define the mechanism by which Itmap1 protects against pancreatitis,
we evaluated apoptotic cell death, leukocyte influx, and trypsinogen
activation in the cerulein-hyperstimulated pancreas. Measurement of
myeloperoxidase activity and evaluation of pancreatic histology
indicate that Itmap1 deficiency does not predispose to exaggerated
mononuclear cell invasion or sequestration during pancreatitis. Thus,
Itmap1 probably does not function by dampening the inflammatory
response in the pancreas, and it is not likely that Itmap1 deficiency
is associated with altered NF B activation, another presumed major
determinant of experimental pancreatitis. We do find that Itmap1
deficiency increases the susceptibility of the acinar cell to apoptotic
cell death. Increased cell death due to apoptosis would be expected to
provide little additional inflammatory stimulus and may explain the
equivalence of inflammatory markers between genotypes in the cerulein
hyperstimulation model. Surprisingly, measurements of both trypsin
activity and TAP revealed that Itmap1 / mice
had significantly less trypsinogen activation than did
Itmap1+/+ mice. This decrease in trypsin
activation is not due to less trypsinogen within zymogen granules,
because Western blot analysis of zymogen granule contents reveals
similar amounts in normal and Itmap1-deficient mice. This finding shows
that Itmap1 does not protect the pancreas by decreasing trypsin
activation or activity when pancreatitis is induced.
The decreased trypsinogen activation in the face of more severe
pancreatitis raises questions about the contribution of trypsin to the
course of cerulein-induced pancreatitis. It has been generally assumed
that pancreatitis is associated with a gain of trypsin function, but
some have argued that the activation of trypsin during pancreatitis is
protective against the action of other, more deleterious digestive
enzymes (27). Our results add credence to the hypothesis that trypsin
activation serves as a protective mechanism during acute pancreatitis.
Although in cathepsin B-deficient mice decreased trypsinogen activation
correlated with some parameters indicating less severe cerulein-induced
pancreatitis (4), pancreatic inflammation demonstrated little or no
change. The unchanged inflammation in the cathepsin B-deficient mice,
in accord with our findings, dissociates the trypsin activation from
pancreatic inflammation. The greater severity of pancreatitis we find
with Itmap1 deficiency may be due to the compartment in which cathepsin
B modulates trypsinogen activation differing from that of Itmap1.
Cathepsin B activates trypsinogen in vacuoles newly formed during
hyperstimulation containing a mixture of zymogens and lysosomal
hydrolases, whereas Itmap1 localizes to zymogen granules and is most
likely to modulate trypsinogen activation within the zymogen granule
itself. Our results underscore the complexity of the mechanisms
involved in protecting the pancreas against damage and the initial
events that trigger pancreatitis.
The location and structure of Itmap1 further suggest possible roles for
this zymogen membrane protein. A submembranous matrix of proteoglycans
resides on the inner surface of the zymogen granule membrane. It
consists predominantly of poorly characterized proteoglycans, although
the most abundant component, Muclin, has been described (28). Muclin, a
300-kDa glycoprotein, with sulfated O-linked carbohydrate
chains is, like Itmap1, a ZP domain protein. The major glycoprotein of
the zymogen granule membrane, GP2, links with the proteoglycans of the
submembranous matrix and helps keep them tightly associated with the
membrane (29). Interestingly, GP2 is also a ZP domain-containing
protein (30, 31). By analogy to other ZP domain proteins, we propose
that Itmap1 interacts with the submembranous fibrillar ZP domain matrix
where it may contribute to zymogen assembly or stability. Given the
finding that the distribution and relative abundance of components of zymogen granule contents does not differ between
Itmap1+/+ and Itmap1 /
mice, it is unlikely that Itmap1 plays an important role in the sorting
of proteins into the zymogen granule. Further studies designed to
elucidate the role of Itmap1 in zymogen granule stability and trypsin
activation are in progress.
We have described a new pancreatic glycoprotein that is present on
zymogen granule membranes. Importantly, although the full spectrum of
its actions may not yet be defined, Itmap1 significantly attenuates the
course of acute pancreatitis in mice. Because Itmap1 is also expressed
in the human pancreas,2
dysregulation of Itmap1 expression may contribute to variation in
susceptibility to pancreatitis after toxin exposure, e.g.
alcohol abuse, and in genetic diseases such as cystic fibrosis. Future efforts will be essential to determine the role of Itmap1 in human disease and whether modulation of Itmap1 activity will prove useful as
a therapeutic intervention.
 |
ACKNOWLEDGEMENTS |
We thank Dr. John Kasik for providing the
Itmap1 full-length cDNA and helpful discussions, Marilyn Levy for
assistance with electron microscopy, and Drs. Jonathan Gitlin and David
Alpers for manuscript review.
 |
FOOTNOTES |
*
This work was supported by grants from the March of Dimes,
Burroughs Wellcome Fund, and National Institutes of Health Grants AA12957 (to L. J. M.) and DK52574 (to M. E. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Both authors contributed equally to this work.
§
To whom correspondence should be addressed: Washington University
School of Medicine, Box 8208, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-286-2847; Fax: 314-286-2893; E-mail:
Muglia_L@kids.wustl.edu.
Published, JBC Papers in Press, October 24, 2002, DOI 10.1074/jbc.M204159200
2
M. E. Lowe and L. J. Muglia,
unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
ZP, zona pellucida;
CDE, choline-deficient, ethionine-supplemented;
CUB, complement
subcomponents C1r/C1s, sea urchin Uegf protein, bone morphogenetic
protein-1;
ES, embryonic stem;
Itmap1, integral membrane-associated
protein-1;
IEF, isoelectric focusing;
MPO, myeloperoxidase;
TAP, trypsinogen activation peptide;
PBS, phosphate-buffered saline;
MOPS, 4-morpholinepropanesulfonic acid;
MES, 4-morpholineethanesulfonic acid;
CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid;
TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end
labeling.
 |
REFERENCES |
| 1.
|
Steinberg, W.,
and Tenner, S.
(1994)
N. Engl. J. Med.
330,
1198-1210[Free Full Text]
|
| 2.
|
Bettinger, J. R.,
and Grendell, J. H.
(1991)
Pancreas
6 Suppl. 1,
S2-S6
|
| 3.
|
Whitcomb, D. C.,
Gorry, M. C.,
Preston, R. A.,
Furey, W.,
Sossenheimer, M. J.,
Ulrich, C. D.,
Martin, S. P.,
Gates, L. K.,
Amann, S. T.,
Toskes, P. P.,
Liddle, R.,
McGrath, K.,
Uomo, G.,
Post, J. C.,
and Ehrlich, G. D.
(1996)
Nat. Genet.
14,
141-145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Halangk, W.,
Lerch, M. M.,
Brandt-Nedelev, B.,
Roth, W.,
Ruthenbuerger, M.,
Reinheckel, T.,
Domschke, W.,
Lippert, H.,
Peters, C.,
and Deussing, J.
(2000)
J. Clin. Invest.
106,
773-781[Medline]
[Order article via Infotrieve]
|
| 5.
|
Steer, M.
(1993)
in
The Pancreas: Biology, Pathobiology, and Disease
(Go, V.
, Dimagno, E.
, Gardner, J.
, Lebenthal, E.
, Reber, H.
, and Scheele, G., eds), Second Ed.
, pp. 581-591, Raven Press, New York, NY
|
| 6.
|
Kasik, J. W.
(1998)
Biochem. J.
330,
947-950
|
| 7.
|
Killick, R.,
Legan, P.,
Malenczak, C.,
and Richardson, G.
(1995)
J. Cell Biol.
129,
535-547[Abstract/Free Full Text]
|
| 8.
|
De Lisle, R. C.,
and Ziemer, D.
(2000)
Eur. J. Cell Biol.
79,
892-904[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Tybulewicz, V.,
Crawford, C.,
Jackson, P.,
Bronson, R.,
and Mulligan, R.
(1991)
Cell
65,
1153-1163[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Deng, C.,
Wynshaw-Boris, A.,
Shen, M. M.,
Daugherty, C.,
Ornitz, D. M.,
and Leder, P.
(1994)
Genes Dev.
8,
3045-3057[Abstract/Free Full Text]
|
| 11.
|
Muglia, L. J.,
Jenkins, N. A.,
Gilbert, D. J.,
Copeland, N. G.,
and Majzoub, J. A.
(1994)
J. Clin. Invest.
93,
2066-2072[Medline]
[Order article via Infotrieve]
|
| 12.
|
Muglia, L. M.,
Schaefer, M. L.,
Vogt, S. K.,
Gurtner, G.,
Imamura, A.,
and Muglia, L. J.
(1999)
J. Neurosci.
19,
2051-2058[Abstract/Free Full Text]
|
| 13.
|
De Lisle, R. C.,
Schulz, I.,
Tyrakowski, T.,
Haase, W.,
and Hopfer, U.
(1984)
Am. J. Physiol.
246,
G411-G418[Abstract/Free Full Text]
|
| 14.
|
Wishart, M. J.,
Andrews, P. C.,
Nichols, R.,
Blevins, G. T.,
Logsdon, C. D.,
and Williams, J. A.
(1993)
J. Biol. Chem.
268,
10303-10311[Abstract/Free Full Text]
|
| 15.
|
Gross, G.,
Imamura, T.,
Vogt, S. K.,
Wozniak, D. F.,
Nelson, D. M.,
Sadovsky, Y.,
and Muglia, L. J.
(2000)
Am. J. Physiol.
278,
R1415-R1423[Abstract/Free Full Text]
|
| 16.
|
Christie, D. L.,
and Palmer, D. J.
(1990)
Biochem. J.
270,
57-61[Medline]
[Order article via Infotrieve]
|
| 17.
|
Lampel, M.,
and Kern, H. F.
(1977)
Virch. Arch. A Pathol. Anat. Histol.
373,
97-117
|
| 18.
|
Adler, G.,
Hupp, T.,
and Kern, H. F.
(1979)
Virch. Arch. A Pathol. Anat. Histol.
382,
31-47
|
| 19.
|
Niederau, C.,
Niederau, M.,
Luthen, R.,
Strohmeyer, G.,
Ferrell, L. D.,
and Grendell, J. H.
(1990)
Gastroenterology
99,
1120-1127[Medline]
[Order article via Infotrieve]
|
| 20.
|
McDonald, M. K.,
and Ellis, S.
(1975)
Life Sci.
17,
1269-1276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Jaffrey, C.,
Eichenbaum, D.,
Denham, D. W.,
and Norman, J.
(1999)
Pancreas
19,
377-381[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Lombardi, B.,
and Rao, N. K.
(1975)
Am. J. Pathol.
81,
87-99[Abstract]
|
| 23.
|
Lombardi, B.,
Estes, L. W.,
and Longnecker, D. S.
(1975)
Am. J. Pathol.
79,
465-480[Abstract]
|
| 24.
|
Thim, L.,
and Mortz, E.
(2000)
Regulatory Peptides
90,
61-68[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Mashimo, H., Wu, D. C.,
Podolsky, D. K.,
and Fishman, M. C.
(1996)
Science
274,
262-265[Abstract/Free Full Text]
|
| 26.
|
Rao, K. N.,
Tuma, J.,
and Lombardi, B.
(1976)
Gastroenterology
70,
720-726[Medline]
[Order article via Infotrieve]
|
| 27.
|
Lerch, M. M.,
and Gorelick, F. S.
(2000)
Med. Clinics N. Am.
84,
549-563[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
De Lisle, R. C.
(1994)
J. Cell. Biochem.
56,
385-396[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Freedman, S. D.,
and Scheele, G. A.
(1993)
Eur. J. Cell Biol.
61,
229-238[Medline]
[Order article via Infotrieve]
|
| 30.
|
Hoops, T. C.,
and Rindler, M. J.
(1991)
J. Biol. Chem.
266,
4257-4263[Abstract/Free Full Text]
|
| 31.
|
Fukuoka, S.,
Freedman, S. D.,
and Scheele, G. A.
(1991)
Proc. Natl. Acad. Sci. U. S. A.
88,
2898-2902[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. Chen, P. J. Ulintz, E. S. Simon, J. A. Williams, and P. C. Andrews
Global Topology Analysis of Pancreatic Zymogen Granule Membrane Proteins
Mol. Cell. Proteomics,
December 1, 2008;
7(12):
2323 - 2336.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. De Lisle, W. Xu, B. A. Roe, and D. Ziemer
Effects of Muclin (Dmbt1) deficiency on the gastrointestinal system
Am J Physiol Gastrointest Liver Physiol,
March 1, 2008;
294(3):
G717 - G727.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yamazaki, T. Adachi, K. Sato, Y. Yanagisawa, H. Fukata, N. Seki, C. Mori, and M. Komiyama
Identification and Characterization of Novel and Unknown Mouse Epididymis-Specific Genes by Complementary DNA Microarray Technology
Biol Reprod,
September 1, 2006;
75(3):
462 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yu, S. A. Michie, and A. W. Lowe
Absence of the Major Zymogen Granule Membrane Protein, GP2, Does Not Affect Pancreatic Morphology or Secretion
J. Biol. Chem.,
November 26, 2004;
279(48):
50274 - 50279.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|